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Abstract
Background: WHO reported more than 100,000 maternal death due to obstetric 
hemorrhage annually, in other hand  Cesarean Section (CS) is a common surgery 
done to save mother and child with one of the complications is hemorrhage. 
tranexamic acid (TXA) as antifibrinolytic might improve maternal outcome by 
decreasing blood loss in CS.
Objectives:Determine effectiveness and safety of tranexamic acid in decreasing 
blood loss in cesarean section.
Method:A prospective, double blinded, randomized controled  study in Obstetrics 
and Gynecology Department of Southern Philippines Medical Center. The 
participants are 124 women  underwent CS, 62 women given tranexamic acid after  
cord cut compared to 62 given placebo. Estimated blood loss, cardiac rate, systolic 
blood pressure before and after CS, events during CS and additional medicines. 
Hemoglobin and hematocrit was taken before and after CS, course in the ward, 
blood transfusion, adverse events, mortality and length of hospital stay were 
compared.
Results: Socio demographic, clinical profile, events after interventions, need of 
additional medicines and complications are similar for both group (p-value>0.05). 
The cardiac rate after CS is significantly higher in TXA group (tranexamic:85.1±11.5 
placebo:80.1±15. 6, p-value=0.0441), but still in normal range. 
Conclusion: Tranexamic acid is not recommended to be given routinely  to reduce 
blood loss in CS, instead  its more beneficence to abort severe bleeding hence its 
should be available during CS.  There  was no  adverse events recorded in both 
treatment and placebo group showed safety of tranexamic acid.
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Abstrak
Latar belakang: WHO melaporkan lebih dari 100.000 kematian ibu per tahun 
disebabkan oleh perdarahan obstetric, di lain pihak, seksio sesarea sebagai 
tindakan penyelamatan terhadap ibu dan bayi yang paling sering dilakukan dapat 
mengakibatkan komplikasi perdarahan. Asam traneksamat sebagai antifibrinolitik 
memberikan harapan dalam meningkatkan keselamatan ibu dengan menurunkan 
volume darah yang hilang dalam seksio sesarea.
Obyektif: Menentukan efektivitas dan keamanan asam traneksamat dalam 
menurunkan volume darah yang hilang dalam seksio sesarea.
*  Resident Physician of Obstetrics and Gynecology Department of Southern Philippines Medical Center; Staff of Medical 
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Metode: Studi prospektif acak terkontrol buta ganda di Departemen Obstetri dan 
Ginekologi di Southern Philippines Medical Center. Peserta adalah 124 wanita 
yang menjalani seksio sesarea, 62 wanita mendapat asam traneksamat setelah 
pemotongan tali pusat dan 62 mendapat placebo. Perkiraan volume darah yang 
hilang, frekuensi denyut jantung, tekanan darah sistolik sebelum dan sesudah 
seksio, kejadian saat dilakukan seksio dan tambahan terapi yang diberikan dicatat. 
Demikian pula dengan hemoglobin dan hematokrit sebelum dan sesudah seksio, 
kejadian di ruang rawat inap, transfusi darah, angka kematian dan durasi rawat inap.
Hasil: Sosio demografi, profil kliinis, kejadian setelah perlakuan, tindakan atau 
terapi tambahan yang diperlukan sebanding untuk kedua kelompok (p-value>0.05). 
Frekuensi denyut jantung setelah seksio lebih tinggi secara signifikan pada 
kelompok dengan asam traneksamat (traneksamat:85.1±11.5 plasebo:80.1±15.6, 
p-value=0.0441), namun masih dalam batas normal secara klinis.
Simpulan: Asam traneksamat tidak disarankan untuk rutin diberikan untuk 
menurunkan volume darah yang hilang pada tindakan seksio sesarea, namun 
penggunaannya lebih dianjurkan pada perdarahan hebat sehingga obat ini sebaiknya 
tersedia pada saat dilakukan seksio. Tidak ada efek samping pada kedua kelompok 
perlakuan sehingga disimpulkan asam traneksamat aman digunakan.
Kata kunci: asam traneksamat, perdarahan, seksio sesarea
INTRODUCTION
A study by WHO found that every 
year around 536,000 women die from 
pregnancy and childbirth-related causes. 
It is no longer a revelation to consider that 
obstetric hemorrhage is the leading cause at 
approximately 35%.  From the 14 million 
participants who suffer from postpartum 
hemorrhage each year, 1-2% dies in about 
2–4 hours (1). 
In the country profile published by the 
WHO, Philippines  has been cited to be one 
of the countries with increasing prevalence of 
Cesarean Sections.  With an improvement in 
maternal and perinatal health as observed in 
the decreasing maternal mortality ratio from 
209 in the year 1995 to only 99 in 2010 (9). 
However, in a study commissioned by SEA-
ORCHID noted high incidence of postpartum 
hemorrhage in 9 tertiary care centers across 
four Asian countries including the Philippines 
with as much as 30% of its procedures(6).
Guidelines on the ideal use of obstetric 
interventions and uterotonic drugs were 
already available long before but does 
not include the treatment of hemostatic 
abnormalities as such have been considered 
as consequences of uncontrolled bleeding. 
Hence, hemostatic drugs are not routinely 
used (10,11,12).
It is now known, however, that a 
relationship exists between a decrease in 
fibrinogen and outcome of patients who 
suffered from postpartum hemorrhage. Also, 
the tissue injury as the initiating event in the 
problem can change the hemostatic paradigm 
toward increased fibrinolysis, thus promoting 
vicious sequence of coagulopathy and 
bleeding (13,14).
Anti-fibrinolytic drugs like TXA 
have been proven to reduce transfusion 
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requirements as well as blood loss in 
elective cardiac and orthopaedic surgeries, 
but there are no obstetric cases included. 
Cochrane Database Systematic review, 
which summarizes 211 RCTs with 20,781 
participants shows that tranexamic acid 
reduced the risk of blood transfusion  by a 
relative 39% (RR=0.61, 95%CI 0.54 to 0.69). 
TXA also reduced transfusion needed by 1.1 
units  (95%CI 0.64 to 1.59) (15).
A randomized clinical trial done in 180 
woman by Gai 2004 showed TXA may reduce 
extent of bleeding from the end of CS to two 
hours postpartum 42.75±40.45 ml in study 
group versus 73.98±77.09 ml in the placebo 
group (p 0.001) and was not associated with 
any side effects or complications (16). However, 
this finding was not significant for routine use 
of TXA as prophylactic. 
This study aims to explore more on 
the effictiveness of the blood loss reduction 
capabilities of  TXA, and its safety to be 
formally introduced in the local setting and be 
a part of the routine management to prevent 
postpartum hemorrhage as adjunct to the 
use of uterotonic agent as current standard 
management.
Research Question
The study compares the effectiveness 
and safety of TXA to placebo in decreasing 
blood loss after CS. 
Significance of the Study
An effective management of postpartum 
hemorrhage could help significantly to reduce 
maternal mortality and morbidity. Anti-
fibrinolytic therapy might actually reduce the 
problems related to hemorrhage, including 
the need for hysterectomy, the risk of severe 
anemia and the need for blood transfusion, 
and its associated morbidities.
METHODOLOGY
This is a double-blind prospective case 
control study  . The observer and patient  were 
blinded while the researcher did randomization 
and kept the records. The observer was the 
anesthesiologist who estimate blood loss, 
took initial and repeat blood pressure and 
cardiac rate examination at the operating 
room.  The study period was from June to 
July 2013. One hundred and twenty four (124) 
subjects  enrolled in the study. Inclusion 
Criteria:This study  performed on all pregnant 
women of  legal age  who came to Southern 
Philippines Medical Center for anticipated 
delivery and gave consent to join the study. 
Exclusion Criteria: Pregnant  women 
who have histories or  current problems as 
thrombosis (pulmonary embolism, deep 
vein thrombosis), post-cardiac surgery, 
cerebrovascular accident, sub-arachnoid 
hemorrhage, gravidocardiac, toxic goiter, 
allergy to tranexamic acid, defective color 
vision, antyphospholipid syndrome, SLE, 
prolonged immobilization/ bed rest (more 
than 7 days), pelvic masses such as large 
myoma uteri >6cm, ovarian new growth, 
planned Cesarean hysterectomy, severe 
hemorrhage, unconscious, mentally retarded, 
psychiatric patients, patient in pains, in active 
labor ( more than 4 cm cervical dilatation) 
, and patient with indication for direct  to 
Operating Room on admission.
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Intervention and Comparison
In TXA group, the researcher gave 
TXA 1g diluted in 10cc NaCl 0.9%  slow 
intravenous  immediately  after the cord is cut. 
In the placebo  group 20cc NaCl 0.9% were 
given.  Oxytocin 5 iu slow IV were given to 
the two treatment groups followed by 10 iu 
in D5LR 1L to run 120cc/hour for 8 hours. 
Parameters of blood pressure and cardiac rate 
taken before the procedure started and at the 
end of the procedure. Blood loss and all events 
during surgery such as adhesion, laceration, 
hematoma, uterine atony, duration of surgery, 
and its related management (adhesiolysis, 
repair of laceration, additional uterotonic 
agent, arterial ligation, hysterectomy) will be 
recorded. The patients were followed up in the 
ward. Hemoglobin and hematocrit repeated 
within 48-72 hours after surgery or before 
blood transfusion once blood transfusion 
needed before 48 hours. The length of hospital 
stay recorded.
Data handling and analysis
Data  encoded into the computer 
using the EPI Info version 3.5.3.  The same 
software shall be used to analyze the data. 
Descriptive statistics  used to analyze the data 
like the mean and standard deviation for the 
quantitative variable and proportion for the 
qualitative variable. The independent T test 
used to compare the mean blood loss, blood 
pressure, cardiac rate, and blood transfusion. 
Comparison of the mean hemoglobin and 
hematocrit  at baseline and after Cesarean 
Section by the Treatment Group shall be 
analyzed using the repeated measures analysis 
of variance. Chi-square used in comparing the 
mortality and hysterectomy by the treatment 
group.  The level of significance set at 0.05.
RESULT
There were a total of 124 patients included in 
the study of which 50% received TXA while 
the other 50% acted as positive placebo. 
Table 1. Socio-demographic and Clinical Profile of the Participants
Profile Tranexamic Acid n=62 Placebo n=62 P value
Age (Mean ± SD) 26.9 ± 5.2 28.6 ± 6.9 0.1039
Gravidity (Mean ± SD) 2.2 ± 0.9 2.1 ± 0.9 0.4979
Parity (Mean ± SD) 1.1 ± 0.9 1.0 ± 0.8 0.3574
Weight (Mean ± SD) 63.5 ± 9.5 64.0 ± 9.9 0.7744
Height (Mean ± SD) 151.3 ± 6.4 150.4 ± 6.8 0.4377
Indication for CS   (n %)
   PIH 1 (1.6) 0 1.0000
Abruptio Placenta 0 1 (1.6) 1.0000
   Placenta Previa 1 (1.6) 1 (1.6) 1.0000
   Arrest Disorder 6 (9.7) 9 (14.5) 0.4087
Fetal Distress 6 (9.7) 6 (9.7) 1.0000
Malpresentation 7 (11.0) 10 (16.1) 0.4335
   Repeat CS 41 (66.1) 35 (56.5) 0.2686
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Hemoglobin  (mean ± SD) 
Baseline
124.6 ± 12.9 127.2 ± 12.9 0.2626
Hematocrit  (mean ± SD) 
Baseline
0.38 ± 0.03 0.38 ± 0.04 0.9798
Systolic Blood Pressure 
before CS (mean±SD)
119.7 ± 15.3 120.2 ± 15.7 0.8577
Cardiac Rate  before CS 
(mean ± SD)
86.5 ± 9.6 88.2 ± 17.4 0.5067
There is no significant difference in the events after the intervention except for the cardiac rate 
after the CS.  The cardiac rate among the placebo group is significantly lower than the TXA 
group (p-value=0.0441)
Table 2.  Events after Intervention
Variable Tranexamic Acid n=62 Placebo n=62 P value
Estimated Blood Loss (mean ± SD) 424.2 ± 253.1 406.9 ± 175.1 0.9061
Hemoglobin  (mean ± SD) After CS 110.8 ± 15.9 109.9 ± 16.8 0.7629
Change of Hemoglobin  (mean ± SD) 
After CS
13.6 ± 12.2 17.8 ± 15.5 0.0924
Hematocrit  (mean ± SD)After 0.3 ± 0.04 0.2 ± 0.01 0.3222
Change of Hematocrit  (mean ± SD) 
After CS
0.04 ± 0.03 0.03 ± 0.02 0.3009
Systolic Blood Pressure after  (mean 
± SD)
113.4 ± 14.4 111.0 ± 19.3 0.4302
Cardiac Rate after  CS (mean ± SD) 85.1  ± 11.5 80.1 ± 15.6 0.0441
Duration of CS 59.5 ± 23.2 63.1 ± 23.5 0.3934
Table 3. Comparison of Surgical Events/ Additional Medicines
Variable Tranexamic Acid   n=62 Placebo  n=62 P value
Adhesiolysis 2 (3.2) 2 (3.2) 1.000000
Evacuation of Hematoma - - -
Uterine atony 4 (6.5) 3 (4.8) 1.000000
Repair of Laceration 3 (4.8) 4 (6.5) 1.000000
Hysterectomy  (n %) 1 (1.6) 0 1.000000
Additional medicine/s:
Need for Oxytocin 2 (3.2) 3 (4.8) 1.000000
Mean amount of Oxytocin 
(international unit) ±SD
10.0 ± 0 11.7 ± 2.9 0.495025
Need for Methyl Ergometrin 1 (1.6) 1 (1.6) 1.000000
Mean amount of Methyl 
Ergomethryn (mg) ±SD
20 ± 0 20 ± 0 -
Need for Tranexamic Acid 1 (1.6) 4 (6.5) 0.364711
Mean amount of Tranexamic 
Acid (mg) ±SD
1000.0 ± 0 1000.0 ± 0 -
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 Table 4. Comparison of Complication by Treatment Group
Variable Tranexamic Acid n=62 Placebo n=62 P value
Mortality (n %) - - -
Length of hospital stay  (mean ± 
SD)
4.1 ± 1.3 4.3 ±1.0 0.3479
Need for Blood Transfusion  3 (4.8) 2 (3.2) 1.000000
Mean volume of  blood transfused 
( ±SD)
1080.0 ± 0 315.0 ± 7.1 -
Adverse events in terms of gastrointestinal problems, allergic reaction and thrombosis event did 
not occur in both groups.
DISCUSSION OF RESULT
This study showed no significant 
differenc eof estimated blood loss, systolic 
blood pressure and changes in hemoglobin 
and hematocrit  in treatment and placebo 
group (p-value>0.05). The cardiac rate after 
CS is significantly higher in TXA group 
(tranexamic:85.1±11.5 placebo:80.1±15.6, 
p-value=0.0441), but still in normal range so 
there is no clinical significant. Surgical events, 
duration of CS, need of additional medicines 
and length of stay is similar for both group.
No adverse event such as thrombosis events, 
nausea and vomit  reported for both group.
Study on TXA given prior to CS carried 
out by Gai et al in China and Gohel et al in India 
showed that TXA significantly reduces bleeding 
from the time of placental delivery to 2 hours 
post partum. The study showed significant 
decrease in the incidence of > 500 ml blood loss 
in the study group as compared to placebo group 
(Gai:P-0.029, Gohel:P-0.049 ). Zheng et al also 
reported similar results on  vaginal delivery. A 
study by Ducloy-Bouthor by giving high dose 
TXA in post partum hemorrhage also showed 
significant reduction of blood loss(16,28,29).
Possible reason of different research 
outcome to previous studies are different time 
of administration, in study by Gai et al and 
Gohel et al TXA is given 10 and 20 minutes 
before skin incision, early administration of 
TXA give advantage from the start, in this 
study TXA given after delivery of  baby and 
cord cut to prevent transplacental transfer of 
TXA to the newborn(16,28). 
Immediate intervention such as 
additional medicines (oxytocin, methyl 
ergometrin, tranexamic acid) and surgical 
management (repair of laceration, 
hysterectomy) was done appropriately to 
avoid adverse events and complication lead to 
comparable outcome for both treatment and 
placebo group. 
Intraoperative assessment of 
progressive blood loss that require additional 
TXA are more common  in placebo than in 
treatment group (t:1; p:4;  p-value=0.364711) 
although not significant, this finding showed 
importance of this medicine to prevent severe 
hemorrhage (comparable estimated blood 
loss of treatment and placebo group ) hence 
assurance of  availability of  TXA is important 
during surgery.
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CONLUSION 
The sociodemographic and clinical 
profile of the patients in the tranexamic acid 
group and the placebo group showed no 
significant difference (p-value>0.05). Events 
after the intervention is not significant except 
for the cardiac rate after the CS where the 
TXA group showed a significantly higher rate 
than the placebo group (p-value=0.0441). The 
surgical events, need for additional medicines 
and complications are similar in the 2 
treatment groups (p-value>0.05). There is no 
significant difference in the adverse events in 
the 2 treatment groups (p-value>0.05).
Recommendation
TXA is not recommended to be used 
routinely to reduce blood loss in CS. Instead, 
TXA is more beneficence to be used to abort 
severe bleeding hence its should be available 
as one of emergency medicine during CS. 
There  was no  adverse events recorded in 
both treatment and placebo group showed 
safety of TXA. More studies are needed to 
determine effectiveness  of TXA to reduce 
postpartum hemorrhage,  different variables 
to investigate  such as early administration 
of TXA, and possible use of TXA in vaginal 
delivery.
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